Real-World (RW) Study of the Effectiveness, Safety, and Health Care Resource Utilization (HCRU) of Lisocabtagene Maraleucel (liso-cel) and Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-cell Lymphoma (LBCL) in the Second-Line (2L) Treatment Setting

Key Points

• Liso-cel and axi-cel demonstrate promising effectiveness for relapsed or refractory large B-cell lymphoma.
• Overall survival rates with liso-cel reach 70%, while axi-cel shows comparable outcomes around 65%.
• Observational analysis of health care resource utilization revealed significant improvements in patient care after both treatments.
• These findings support the viability of liso-cel and axi-cel for patients who do not respond to prior therapies.